Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36. - Wikidata - wikimedia - TriplyDB

Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36.

Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36.

http://www.wikidata.org/entity/Q34174815

about

Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies Engineering antibody-like inhibitors to prevent and treat HIV-1 infection.Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.Germlining of the HIV-1 broadly neutralizing antibody domain m36 Antibody engineering for increased potency, breadth and half-life.Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity.Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection Bispecific antibodies for viral immunotherapy.HIV antibodies for treatment of HIV infection.Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.Antibody therapies for the prevention and treatment of viral infections.Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice.Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity.HIV Entry and Its Inhibition by Bifunctional Antiviral Proteins Engineering multi-specific antibodies against HIV-1

P2860

Q28068946-E798CD5C-D95F-45E0-BFAF-8E2817A888E6 Q30490945-BABE380A-EF92-4F31-818C-9DD871780400 Q33620546-316EEBEC-0402-4C1E-814B-824AC55ECD77 Q34531219-1CC9E48A-CBC6-4474-ABB8-2F9A569B6C13 Q35171173-4A98CE86-5AF9-46E2-A403-1156E3E01125 Q35575206-5F9976CE-CAF6-473C-84E0-58DDE9AF6458 Q36334359-D3DA3176-44B7-44BA-80CE-28A058C68AD3 Q36393594-A9E07FE8-3614-4EB1-A9A9-E8EACADCC3B7 Q38977425-7524338F-D31C-485C-94B9-4EB5CF1661C5 Q38992408-3DA8B0C7-FC0D-42F3-9BCE-25BB9ECE5E2C Q39108716-9E14912B-DE9B-4DB1-90F8-3374E3A59036 Q39238361-6ED74784-3D1E-4CFE-98DA-2B4054006BF1 Q47143843-D9D494E4-AC27-4D89-BAFE-10E2E194010D Q52673965-4513797E-4683-4848-9D50-F03E6B2F16B4 Q52692811-1EC9F8F4-964E-416F-8F1C-D9E7A4785492 Q53081267-F49541C9-8D0D-48CA-8C34-25218C80C51C Q58555325-D9315BB1-7B6A-4389-9BBA-D21A2DC70137 Q58696428-460ADEDC-65BE-4390-B57D-C7CA2724D356

P2860

Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36.

http://www.wikidata.org/entity/Q34174815

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Rational design and characteri ...... neutralizing antibody iMabm36.

@ast

Rational design and characteri ...... neutralizing antibody iMabm36.

@en

Rational design and characteri ...... neutralizing antibody iMabm36.

@nl

type

label

Rational design and characteri ...... neutralizing antibody iMabm36.

@ast

Rational design and characteri ...... neutralizing antibody iMabm36.

@en

Rational design and characteri ...... neutralizing antibody iMabm36.

@nl

prefLabel

Rational design and characteri ...... neutralizing antibody iMabm36.

@ast

Rational design and characteri ...... neutralizing antibody iMabm36.

@en

Rational design and characteri ...... neutralizing antibody iMabm36.

@nl

P1433

Q34174815-33B27E1E-C0AF-4521-ADF1-310033A10705

P1476

Q34174815-0B80C197-1DF9-4BA3-A4AC-DD26D0384D82

P2093

Q34174815-257BD5AC-891F-4709-8176-9950FA02F70C

Q34174815-80FF07E2-67F0-48A9-8876-5A881AA16379

Q34174815-811980E1-24CA-45C8-B26B-E448E361E97A

Q34174815-BDA3B3F2-8506-4304-B336-173364031CDF

Q34174815-C2380E64-5167-412B-9F79-4E156E9CBB3D

Q34174815-C9E9BB9A-895B-45C7-9ECB-410D6FBD9D30

Q34174815-EAF82107-93F4-4539-9503-F2F9173F1D69

Q34174815-F58F2148-4455-478C-A7FC-B8FBA6EB3A4A

Q34174815-FB6D82C8-6A28-4EC0-8D54-5C4D73CDFA50

P2860

Q34174815-05B00052-E6A5-44D1-B4BB-28DCA9F8607E

Q34174815-0BA69886-A190-4441-A2B5-7716371DAABE

Q34174815-1C70C735-2650-4FD2-956E-A27F7FDA6A0A

Q34174815-24A1E7EC-3877-4B5C-9F58-1E7924CDC4E0

Q34174815-260E1323-D3CB-4274-A5FA-29561F1E26FD

Q34174815-26EAE418-4062-44BB-A0B8-4450FCAEAC8A

Q34174815-2755002D-E5BB-4CF0-8A3C-4BAA5A4FB110

Q34174815-284DD8EE-399C-4612-84AC-55AF4B43B250

Q34174815-2AC8121E-4891-48A2-AF12-8CC82519D2B9

Q34174815-2F712F64-C4F2-40AA-B35D-86A93B7CFC51

P304

Q34174815-CADDC13C-BA86-455F-AB23-AEE99832D40B

P31

Q34174815-22EAC063-0D71-4AFE-A9AE-710D835526B3

P356

Q34174815-900DDD32-2C58-4893-BA22-14FA6D7BF563

P407

Q34174815-A9A3C97D-FF20-4A84-ABAF-96AE7531C798

P433

Q34174815-843AC62C-F25A-4DEF-8C34-FDCBA4E7B108

P478

Q34174815-B994DD81-766E-4EC7-9611-D5535652EA67

P577

Q34174815-8AAF68B9-16C9-4EEA-AA8A-4B807830F1D4

P698

Q34174815-7D25F9F9-9C10-4617-974E-383C4205C92B

P921

Q34174815-3164630A-518C-4210-B862-6C49EB86F5CA

P932

Q34174815-440E7D11-021B-4EDA-8B55-19A30903AB9E

P356

QAI.0000000000000218

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Rational design and characteri ...... neutralizing antibody iMabm36.

@en

P2093

Craig S Pace

http://www.w3.org/2001/XMLSchema#string

David D Ho

http://www.w3.org/2001/XMLSchema#string

Faye Yu

http://www.w3.org/2001/XMLSchema#string

Michael S Seaman

http://www.w3.org/2001/XMLSchema#string

Ming Sun

http://www.w3.org/2001/XMLSchema#string

Neal N Padte

http://www.w3.org/2001/XMLSchema#string

Qihan Li

http://www.w3.org/2001/XMLSchema#string

Xin Yao

http://www.w3.org/2001/XMLSchema#string

Yaoxing Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Increasing the potency and breadth of an HIV antibody by using structure-based rational design

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults

Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates

Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120

Molecular architecture of native HIV-1 gp120 trimers

Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120

Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

P304

473-483

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0000000000000218

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24853313

http://www.w3.org/2001/XMLSchema#string

P921

P932

4163016

http://www.w3.org/2001/XMLSchema#string